D-0052-2025 Class II Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

Recall Details

Product Type
Drugs
Report Date
November 27, 2024
Initiation Date
October 23, 2024
Termination Date
January 5, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
112,770 bottles

Product Description

Ramipril Capsules USP 2.5 mg, a) 90 count (NDC 68180-589-09), b) 100 count NDC 68180-589-01), and c) 500 count (NDC 68180-589-02) bottles, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by Lupin Limited, Goa, India

Reason for Recall

CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor

Distribution Pattern

Product was distributed to 30 wholesalers/distributors who may have further distributed the product nationwide.

Code Information

a) NDC 68180-589-09; Lots G326781, exp. date 30-Sep-25, GA04468, exp. date 31-May-25 b) NDC 68180-589-01; Lots G326763, exp. date 30-Sep-25, GA03041, exp. date 31-Mar-26, GA03725, exp. date 30-Apr-26, GA04402, exp. date 31-May-26, c) NDC 68180-589-02; Lots G326782, exp. date 30-Sep-25, GA04462, exp. date 31-May-26